文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

高危前列腺癌盆腔淋巴结照射联合同步立体定向大分割加速放疗的早期耐受性结局

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2019-01-31

23例高危或淋巴结阳性前列腺癌患者接受前列腺及精囊腺5次37.5至40 Gy的立体定向体部放疗,同期盆腔淋巴结照射25 Gy,多数联合18个月雄激素剥夺治疗。中位随访19个月,急性≥2级胃肠道毒性未见,晚期≥3级泌尿生殖毒性1例(4.5%)。作者认为该方案可行且耐受良好,需继续随访确定长期安全性和疗效。

要点

  • 急性1级胃肠道毒性2例(9.1%),无急性≥2级胃肠道毒性。
  • 急性1、2、3级泌尿生殖毒性分别为7例(31.8%)、8例(36.4%)、1例(4.5%)。
  • 晚期2级胃肠道和泌尿生殖毒性分别为2例(9.1%)和6例(27.3%),晚期≥3级泌尿生殖毒性1例(4.5%)。

核心结论

  • 作者认为前列腺及盆腔淋巴结立体定向体部放疗可行且耐受良好,≥3级泌尿生殖和胃肠道毒性不常见。
  • 作者指出需要继续随访以确定该方案用于高危患者的长期安全性和疗效。

研究设计与样本

  • 本研究为23例高危或淋巴结阳性前列腺癌患者接受前列腺及盆腔淋巴结立体定向体部放疗的毒性评估。
  • 前列腺和精囊腺给予37.5至40 Gy分5次,盆腔淋巴结同期给予25 Gy。
  • 患者一般接受新辅助、同期和辅助雄激素剥夺治疗,疗程18个月。
  • 毒性采用不良事件通用术语标准3.0版评估,中位随访19个月(范围3至48个月)。

主要发现

  • 急性1级胃肠道毒性2例(9.1%),无患者发生急性≥2级胃肠道毒性。
  • 急性1、2、3级泌尿生殖毒性分别见于7例(31.8%)、8例(36.4%)、1例(4.5%)。
  • 晚期2级胃肠道毒性和泌尿生殖毒性分别见于2例(9.1%)和6例(27.3%)。
  • 无晚期≥3级胃肠道毒性,晚期≥3级泌尿生殖毒性(出血性膀胱炎)1例(4.5%),经激光凝固术治疗有效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要继续随访以确定该方案用于高危患者的长期安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate the toxicity of prostate and pelvic lymph node stereotactic body radiation therapy (SBRT) for high-risk prostate cancer. METHODS AND MATERIALS: Twenty-three patients with high-risk or lymph node-positive prostate cancer were treated with SBRT that delivered 37.5 to 40 Gy in 5 fractions to the prostate and seminal vesicles, with concomitant treatment of the pelvic nodes to 25 Gy. In general, patients received neoadjuvant, concurrent, and adjuvant androgen deprivation therapy for a duration of 18 months. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, version 3.0. The median follow-up was 19 months (range, 3-48 months). RESULTS: Acute grade 1 gastrointestinal (GI) toxicities were noted in 2 patients (9.1%). No patient experienced acute grade ≥2 GI toxicity. Acute genitourinary (GU) grade 1, 2, and 3 toxicities were observed in 7 patients (31.8%), 8 patients (36.4%), and 1 patient (4.5%), respectively. Late grade 2 GI and GU toxicities were observed in 2 patients (9.1%) and 6 patients (27.3%), respectively. No late grade ≥3 GI toxicity was noted. Late grade ≥3 GU (hemorrhagic cystitis) was noted in 1 patient (4.5%), which responded to laser fulguration. CONCLUSIONS: SBRT with pelvic lymph node radiation therapy was feasible and well tolerated. The incidence of grade ≥3 GU and GI toxicities was uncommon. Continued follow-up will be required to determine the long-term safety and efficacy of this approach for high-risk patients.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pinitpatcharalert A, Happersett L, Kollmeier M, et al. Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer. Adv Radiat Oncol. 2019. PMID: 31011679. doi:10.1016/j.adro.2018.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。